Abstract:
:Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Devinsky O, Patel AD, Cross JH, et al; GWPCARE3 Study Group. N Engl J Med. 2018;378:1888-1897. BACKGROUND:Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox-Gastaut syndrome, a severe developmental epileptic encephalopathy. METHODS:In this double-blind, placebo-controlled trial conducted at 30 clinical centers, we randomly assigned patients with the Lennox-Gastaut syndrome (age range, 2-55 years) who had had 2 or more drop seizures per week during a 28-day baseline period to receive cannabidiol oral solution at a dose of 20 mg/kg of body weight (20-mg cannabidiol group) or 10 mg/kg (10-mg cannabidiol group) or matching placebo, administered in 2 equally divided doses daily for 14 weeks. The primary outcome was the percentage change from baseline in the frequency of drop seizures (average per 28 days) during the treatment period. RESULTS:A total of 225 patients were enrolled; 76 patients were assigned to the 20-mg cannabidiol group, 73 to the 10-mg cannabidiol group, and 76 to the placebo group. During the 28-day baseline period, the median number of drop seizures was 85 in all trial groups combined. The median percentage reduction from baseline in drop seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group, 37.2% in the 10-mg cannabidiol group, and 17.2% in the placebo group ( P = .005 for the 20-mg cannabidiol group vs placebo group, and P = .002 for the 10-mg cannabidiol group vs placebo group). The most common adverse events among the patients in the cannabidiol groups were somnolence, decreased appetite, and diarrhea; these events occurred more frequently in the higher dose group. Six patients in the 20-mg cannabidiol group and 1 patient in the 10-mg cannabidiol group discontinued the trial medication because of adverse events and were withdrawn from the trial. Fourteen patients who received cannabidiol (9%) had elevated liver aminotransferase concentrations. CONCLUSIONS:Among children and adults with the Lennox-Gastaut syndrome, the addition of cannabidiol at a dose of 10 or 20 mg/kg/d to a conventional antiepileptic regimen resulted in greater reductions in the frequency of drop seizures than placebo. Adverse events with cannabidiol included elevated liver aminotransferase concentrations. (Funded by GW Pharmaceuticals; GWPCARE3 ClinicalTrials.gov number, NCT02224560.) Long-Term Safety and Treatment Effects of Cannabidiol in Children and Adults With Treatment-Resistant Epilepsies: Expanded Access Program Results Szaflarski JP, Bebin EM, Comi AM, et al; CBD EAP Study Group. Epilepsia. 2018;59(8):1540-1548. OBJECTIVE:Since 2014, cannabidiol (CBD) has been administered to patients with treatment-resistant epilepsies (TREs) in an ongoing expanded access program (EAP). We report interim results on the safety and efficacy of CBD in EAP patients treated through December 2016. METHODS:Twenty-five US-based EAP sites enrolling patients with TRE taking stable doses of antiepileptic drugs (AEDs) at baseline were included. During the 4-week baseline period, parents/caregivers kept diaries of all countable seizure types. Patients received oral CBD starting at 2 to 10 mg/kg/d, titrated to a maximum dose of 25 to 50 mg/kg/d. Patient visits were every 2 to 4 weeks through 16 weeks and every 2 to 12 weeks thereafter. Efficacy end points included the percentage change from baseline in median monthly convulsive and total seizure frequency and percentage of patients with ≥50%, ≥75%, and 100% reductions in seizures versus baseline. Data were analyzed descriptively for the efficacy analysis set and using the last-observation-carried-forward method to account for missing data. Adverse events (AEs) were documented at each visit. RESULTS:Of 607 patients in the safety data set, 146 (24%) withdrew; the most common reasons were lack of efficacy (89 [15%]) and AEs (32 [5%]). Mean age was 13 years (range, 0.4-62). Median number of concomitant AEDs was 3 (range, 0-10). Median CBD dose was 25 mg/kg/d; median treatment duration was 48 weeks. Add-on CBD reduced median monthly convulsive seizures by 51% and total seizures by 48% at 12 weeks; reductions were similar through 96 weeks. Proportion of patients with ≥50%, ≥75%, and 100% reductions in convulsive seizures were 52%, 31%, and 11%, respectively, at 12 weeks, with similar rates through 96 weeks. Cannabidiol was generally well tolerated; most common AEs were diarrhea (29%) and somnolence (22%). SIGNIFICANCE:Results from this ongoing EAP support previous observational and clinical trial data, showing that add-on CBD may be an efficacious long-term treatment option for TRE. Randomized, Dose-Ranging Safety Trial of Cannabidiol in Dravet Syndrome Devinsky O, Patel AD, Thiele EA, et al; GWPCARE1 Part A Study Group. Neurology. 2018;90(14):e1204-e1211. OBJECTIVE:To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. METHODS:Patients aged 4 to 10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers could continue in an open-label extension. Multiple pharmacokinetic blood samples were taken on the first day of dosing and at end of treatment for measurement of CBD, its metabolites 6-OH-CBD, 7-OH-CBD, and 7-COOH-CBD, and antiepileptic drugs (AEDs; clobazam and metabolite N-desmethylclobazam [N-CLB], valproate, levetiracetam, topiramate, and stiripentol). Safety assessments were clinical laboratory tests, physical examinations, vital signs, electrocardiograms, adverse events (AEs), seizure frequency, and suicidality. RESULTS:Thirty-four patients were randomized (10, 8, and 9 to the 5, 10, and 20 mg/kg/d CBD groups and 7 to placebo); 32 (94%) completed treatment. Exposure to CBD and its metabolites was dose proportional (AUC0-t). Cannabidiol did not affect concomitant AED levels, apart from an increase in N-CLB (except in patients taking stiripentol). The most common AEs on CBD were pyrexia, somnolence, decreased appetite, sedation, vomiting, ataxia, and abnormal behavior. Six patients taking CBD and valproate developed elevated transaminases; none met criteria for drug-induced liver injury and all recovered. No other clinically relevant safety signals were observed. CONCLUSIONS:Exposure to CBD and its metabolites increased proportionally with dose. An interaction with N-CLB was observed, likely related to CBD inhibition of cytochrome P450 subtype 2C19. Cannabidiol resulted in more AEs than placebo but was generally well tolerated. CLASSIFICATION OF EVIDENCE:This study provides class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well tolerated.
journal_name
Epilepsy Currjournal_title
Epilepsy currentsauthors
Perry MSdoi
10.1177/1535759719835671subject
Has Abstractpub_date
2019-03-01 00:00:00pages
93-95issue
2eissn
1535-7597issn
1535-7511journal_volume
19pub_type
评论,杂志文章abstract::[Box: see text]. ...
journal_title:Epilepsy currents
pub_type: 评论,杂志文章
doi:10.1177/1535759719870514
更新日期:2019-09-01 00:00:00
abstract::Interictal spiking is seen in the EEG of epileptic patients between seizures. To date, the roles played by interictal events in seizure occurrence and in epileptogenesis remain elusive. While interictal spikes may herald the onset of electrographic seizures, experimental data indicate that hippocampus-driven intericta...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1111/j.1535-7511.2006.00146.x
更新日期:2006-11-01 00:00:00
abstract::[Box: see text]. ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1177/1535759719889625
更新日期:2020-01-01 00:00:00
abstract::A large body of evidence that has accumulated over the past decade strongly supports the role of both blood-brain barrier (BBB) dysfunction and perivascular inflammation in the pathophysiology of epilepsy. Recent preclinical studies indicate that prolonged seizure- or brain injury-induced BBB dysfunction and subsequen...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1177/1535759719844750
更新日期:2019-05-01 00:00:00
abstract::It has been known for some time that brain-derived neurotrophic factor (BDNF) is critical to normal development of the CNS, and more recently, studies also have documented the ability of BDNF to modify adult CNS structure and function. Therefore, it is no surprise that BDNF has been linked to diseases, such as epileps...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1111/j.1535-7511.2005.05312.x
更新日期:2005-05-01 00:00:00
abstract::Brain malformations are now widely recognized in many forms of epilepsy. To investigate how malformed brain regions participate in the generation of seizure activity researchers have focused on animal models. Here we describe recent advances in this field. ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1046/j.1535-7597.2001.00011.x
更新日期:2001-09-01 00:00:00
abstract::Recent epidemiological and experimental studies have suggested that certain diuretics may have significant anticonvulsant actions. Potential anticonvulsant mechanisms are discussed in light of the effects of these diuretics on electrolyte balance and synaptic signaling. ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1046/j.1535-7597.2002.00018.x
更新日期:2002-03-01 00:00:00
abstract::Insular seizures are great mimickers of seizures originating elsewhere in the brain. The insula is a highly connected brain structure. Seizures may only become clinically evident after ictal activity propagates out of the insula with semiology that reflects the propagation pattern. Insular seizures with perisylvian sp...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1177/1535759718822847
更新日期:2019-01-01 00:00:00
abstract::Advances in epilepsy treatment are occurring at a rapid pace, and it is challenging for us to keep up with the latest in our field. As we struggle to keep up with the literature and concentrate on our own research and clinical work, we often fail to exercise our imagination and envision what our field will be like in ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.5698/1535-7597.17.4.204
更新日期:2017-07-01 00:00:00
abstract::Regarding efficacy of new antiepileptic drugs (AEDs) for seizure control, there are three important clinical questions. How effective are new AEDs when corrected for the efficacy of placebo? And even more important: How do new AEDs fare in terms of seizure remission compared with established agents? And finally: Have ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.5698/1535-7511-11.1.9
更新日期:2011-01-01 00:00:00
abstract::Deficiency of AMPAR-Palmitoylation Aggravates Seizure Susceptibility Itoh M, Yamashita M, Kaneko M, Okuno H, Abe M, Yamazaki M, Natsume R, Yamada D, Kaizuka T, Suwa R, Sakimura K, Sekiguchi M, Wada K, Hoshino M, Mishina M, Hayashi T. J Neurosci. 2018;38(47):10220-10235. doi:10.1523/JNEUROSCI.1590-18.2018. Epub 2018 Oc...
journal_title:Epilepsy currents
pub_type: 评论,杂志文章
doi:10.1177/1535759719835664
更新日期:2019-03-01 00:00:00
abstract::[Box: see text]. ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1177/1535759719889624
更新日期:2020-01-01 00:00:00
abstract::[Box: see text]. ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1177/1535759719891983
更新日期:2020-01-01 00:00:00
abstract::As the ketogenic diet approaches 100 years of continuous use, we reflect on its successes and consider new avenues of research for the next century. One controversial question is regarding whether ketogenic dietary therapies could be successful first-line treatments for epilepsy. Second, is it possible to mimic the me...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1177/1535759719890337
更新日期:2020-05-01 00:00:00
abstract::[Box: see text]. ...
journal_title:Epilepsy currents
pub_type: 评论,杂志文章
doi:10.1177/1535759719869670
更新日期:2019-09-01 00:00:00
abstract::In 2008, the Food and Drug Administration (FDA) issued a warning that any and all antiepileptic drugs (AEDs) might increase the risk of suicidal ideation, suicide attempt, and completed suicide. Considerable confusion and concern followed regarding the use of these drugs, in general, and specifically for people with e...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1111/j.1535-7511.2010.01382.x
更新日期:2010-11-01 00:00:00
abstract::Depression is the most frequent psychiatric comorbidity in patients with epilepsy. By the same token, patients with depression are at higher risk of developing epilepsy than are controls. Such bidirectional relations raise the question of whether both disorders share common pathogenic mechanisms, presenting with commo...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1111/j.1535-7597.2005.05106.x
更新日期:2005-01-01 00:00:00
abstract:PURPOSE:Established tonic-clonic status epilepticus (SE) does not stop in one-third of patients when treated with an intravenous (IV) benzodiazepine bolus followed by a loading dose of a second antiseizure medication (ASM). These patients have refractory status epilepticus (RSE) and a high risk of morbidity and death. ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1177/1535759720928269
更新日期:2020-09-01 00:00:00
abstract::[Box: see text]. ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1177/1535759719890617
更新日期:2020-01-01 00:00:00
abstract::Current theories on drug resistance in epilepsy include the drug transporter hypothesis, the drug target hypothesis, and a novel approach called the inherent severity model of epilepsy, which posits that the severity of the disease determines its relative response to medication. Valuable as each of these hypotheses is...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1111/j.1535-7511.2008.01289.x
更新日期:2009-03-01 00:00:00
abstract::In the current review, we discuss the process of modeling pediatric epileptic encephalopathies with a focus on in vitro iPSC-based technologies. We highlight the potential benefits as well as the challenges of these approaches and propose appropriate standards for the field. ...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.5698/1535-7597.18.4.240
更新日期:2018-07-01 00:00:00
abstract::Time to Epileptiform Activity and EEG Background Recovery Are Independent Predictors After Cardiac Arrest Westhall E, Rose I, Rundgren M, Bro-Jeppesen J, Kjaergaard J, Hassager C, Lindehammar H, Horn J, Ullen S, Nielsen N, Friberg H, Cronberg T. Clin Neurophysiol. 2018;129:1660-1668. https://doi.org/10.1016/j.clinph.2...
journal_title:Epilepsy currents
pub_type: 评论,杂志文章
doi:10.1177/1535759718822037
更新日期:2019-01-01 00:00:00
abstract::There has been considerable interest in using bumetanide, a diuretic chloride importer NKCC1 antagonist, to reduce intracellular chloride ([Cl(-)](i)) in epileptic neurons, thereby shifting the polarity of GABA from excitatory to inhibitory and ameliorating the actions of GABA-acting antiepileptic drugs. However, a re...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.5698/1535-7511-11.6.192
更新日期:2011-11-01 00:00:00
abstract::Advances in positron emission tomography (PET) techniques have allowed the measurement and imaging of neurotransmitter synthesis, transport, and receptor binding to be performed in vivo. With regard to epileptic disorders, imaging of neurotransmitter systems not only assists in the identification of epileptic foci for...
journal_title:Epilepsy currents
pub_type: 杂志文章
doi:10.1111/j.1535-7511.2005.00064.x
更新日期:2005-11-01 00:00:00
abstract::[Box: see text]. ...
journal_title:Epilepsy currents
pub_type: 评论,杂志文章
doi:10.1177/1535759719870506
更新日期:2019-09-01 00:00:00
abstract::Augmented Reticular Thalamic Bursting and Seizures in Scn1a-Dravet Syndrome Ritter-Makinson S, Clemente-Perez A, Higashikubo B, Cho FS, Holden SS, Bennett E, Chkhaidze A, Eelkman Rooda OHJ, Cornet MC, Hoebeek FE, Yamakawa K, Cilio MR, Delord B, Paz JT. Cell Rep. 2019;26(1):54-64.e6. doi:10.1016/j.celrep.2018.12.018. L...
journal_title:Epilepsy currents
pub_type: 评论,杂志文章
doi:10.1177/1535759719844780
更新日期:2019-05-01 00:00:00